Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Rare Haematology Disorders Market Outlook

The global rare haematology disorders market is expected to grow at a CAGR of 5.6% in the forecast period of 2024-2032.

Global Rare Haematology Disorders Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

High Patient Volume in North America to Aid the Market Growth of Rare Haematology Disorders

The market growth for rare haematology disorders is majorly being supported by the North America market. The region is contributing to the growth of the market as it contains a high patient volume, along with offering an option to get reimbursement for rare haematology disorder treatment products. Further, the treatment of this disorder offers a rich pipeline, and the bulk of these clinical trials are processed in the United States. The region is followed by Europe, which is expected to account for the second-largest market for rare haematology disorders across the globe. This position of Europe is owing to the rising presence of key players. Moreover, Europe offers faster approvals of orphan drugs, which decreases the time-to-market, as a result aiding the market growth.

Rare Haematology Disorders: Market Segmentation

The rare haematology disorder is a set of diseases, which include anaemia-type red blood cell conditions, immuno-disorders, white blood cell dysfunctions, and other platelet-based abnormalities. These are caused when the normal process of blood formation fails, and, instead, abnormal blood cell type is produced, which results in blood cancer and other blood disorders.

Global Rare Haematology Disorders Market  By Dosage Form

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

On the basis of treatment type, the market is divided into:

  • Plasma Derived 
  • Recombinant

Based on disease indication, the industry can be segmented into:

  • Haemoglobin Disorders
  • Rare Blood Cancers
  • Platelet Based Disorders
  • Plasma Disorders
  • Myeloproliferative Disorders
  • Genetic Haematology Disorders
  • Others

By dosage form, the industry is classified into:

  • Oral
  • Injectable
  • Others

The industry is divided on the basis of age group into:

  • Adult (18+)
  • Paediatric (0-17)

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Global Rare Haematology Disorders Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Growing Rare Haemoglobin Disorders and Rare Blood Cancers to Aid the Market Growth of Rare Haematology Disorders

The market growth of rare haematology disorders is driven by the growing occurrence of rare haemoglobin disorders and rare blood cancers, which are predicted to contribute to the highest market share owing to the growing number of authorised products for these indications. Further, the rising demand for injectable dosage in the form segment is expected to propel the market growth as many of the new approvals are in injectable dosage forms.

Key Industry Players in the Global Rare Haematology Disorders Market

The report gives a detailed analysis of the following key players in the global rare haematology disorders market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Bristol-Myers Squibb Company
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche Ltd
  • Emmaus Medical, Inc.
  • Pfizer Inc.
  • Bayer AG
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Treatment Type
  • Disease Indication
  • Dosage Form
  • Age Group
  • Region
Breakup by Treatment Type
  • Plasma Derived 
  • Recombinant
Breakup by Disease Indication
  • Haemoglobin Disorders
  • Rare Blood Cancers
  • Platelet Based Disorders
  • Plasma Disorders
  • Myeloproliferative Disorders
  • Genetic Haematology Disorders
  • Others
Breakup by Dosage Form
  • Oral
  • Injectable
  • Others
Breakup by Age Group
  • Adult (18+)
  • Pediatric (0-17)
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Bristol-Myers Squibb Company
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche Ltd
  • Emmaus Medical, Inc.
  • Pfizer Inc.
  • Bayer AG
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

Rare Haematology Disorders Market Report Snapshots

Rare Haematology Disorders Market Size

Rare Haematology Disorders Treatment Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!

Key Questions Answered in the Report

The global rare haematology disorders market is projected to grow at a CAGR of 5.6% between 2024 and 2032.

The market is being driven by rising disposable incomes, growing incidences of rare haemoglobin disorders and rare blood cancers, and the increasing demand for injectable dosages.

The key trends guiding the market include the increasing R&D activities by key players, the surging approvals of injectable dosages, and the introduction of favourable government initiatives aimed at providing reimbursement for rare haematology disorder treatment products.

The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The leading treatment types in the market are plasma derived and recombinant.

The major disease indications in the industry are haemoglobin disorders, rare blood cancers, platelet based disorders, plasma disorders, myeloproliferative disorders, and genetic haematology disorders, among others.

The major disease indications considered in the market report include haemoglobin disorders, rare blood cancers, platelet based disorders, plasma disorders, myeloproliferative disorders, and genetic haematology disorders, among others.

The major age group segments in the market are adult (18+) and paediatric (0-17).

The major players in the market are Bristol-Myers Squibb Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Emmaus Medical, Inc., Pfizer Inc., and Bayer AG, among others.

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Pricing Plans

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Strategic Solutions for Informed Decision-Making

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-120-433-0800

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124